Novartis AG

Novartis is one of the two Swiss pharma majors, running franchises across cardiovascular, immunology, and oncology. The stock just plunged roughly 12% wiping $20B in market cap on two back-to-back Phase 3 failures — the kind of pipeline setback that resets how the market values the whole R&D machine.

• The clinical data is the direct hit: del-desiran failed in myotonic dystrophy type 1, and pelacarsen's Phase 3 Lp(a) study missed its primary endpoint — two candidates the market had baked into forward revenue estimates. Both were meaningful pipeline pillars, not tail-risk shots on goal.
• The $12B Avidity acquisition now reads harder: the rationale for buying Avidity was next-generation RNA-conjugate expertise, and losing del-desiran validates the exact investor concern (were they overpaying for a program that wouldn't work). A major shareholder is calling for a board shake-up in response.
• The underlying business remains high-return: 30% operating margins, 13% ROIC, 82% gross margins — this isn't a Wells Fargo-level structural break, it's a pipeline failure at a company whose in-market franchise still prints cash. That's the case the bulls will build; the tape is going the other way for now.

The bet is whether the pipeline setback is priced at this level, or whether the activist push forces board-level changes that trigger another leg down. Oct 27 Q3 earnings is the first management response after the failures — a defensive guide plus M&A-strategy walk-back would confirm the reset; a confident 'the pipeline is bigger than these two shots' response could stabilize the tape.